Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior

Journal of Neural Transmission

Volumn 104, Issue 6-7, 1997, Pages 593-603

  Heeringa, M J ^b   D'Agostini, F ^a   DeBoer, P ^b   DaPrada, M ^a   Damsma, G ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

6 Hydroxydopamine; Behavior; Catechol O methyltransferase; Monoamine oxidase; Parkinson's disease; Ro 19 6327; Ro 40 7592; Ro 41 1049

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; LAZABEMIDE; LEVODOPA; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; OXIDOPAMINE; TOLCAPONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; ENZYME INHIBITORS; LEVODOPA; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NITROPHENOLS; OXIDOPAMINE; PICOLINIC ACIDS; RATS; ROTATION; THIAZOLES;

EID: 0030692668     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01291878     Document Type: Article

References (55)

1. Acquas E, Carboni E, de Ree RHA, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59(1): 326-330
2. Barbeau A (1981) The use of L-DOPA in Parkinson's disease: a 20 year follow-up. Trends Pharmacol Sci 2: 297-299
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlation's. J Neurol Sci 21: 297-301
4. Birkmayer W, Riederer P, Youdim MBH, Linnauer W (1975) The potentiation of the akinetic effect after L-DOPA treatment by an inhibitor a M AO-B, deprenyl. J Neural Transm 36: 303-326
5. Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989) Catechol-O-methyltransferease-inhibiting pyrocatechol deratives: synthesis and structure-activity studies. Helv Chim Acta 72: 952-968
6. Brannan T, Martinez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-DOPA and dopamine: an in vivo study in rats. Neurology 42: 683-685
7. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1990) Effect of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988
8. Buu NT (1989) Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibiters. Biochem Pharmacol 38: 1692-1695
9. Buu NT, Angers M (1987) Effect of different monoamine oxidase inhibitors on the metabolism of L-DOPA in the rat brain. Biochem Pharmacol 36: 1731-1735
10. Christmas AJ, Coulson CJ, Maxwell DP, Riddel D (1972) A comparison of the pharmacological and biochemical properties of substrate selective monoamine oxidase inhibitors. Br J Pharmacol 45: 490-503
11. Colzi A, d'Agostini F, Kettler R, Borroni E, DaPrada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm [Suppl] 32: 79-84
12. Da Prada M, Kettler R, Cesura AM, Richards JG (1988) Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol Res Commun [Suppl] 4: 21-33
13. DaPrada M, Kettler R, Keller NH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279-292
14. Davis TL, Roznoski M, Burns RS (1995) Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 10(3): 349-351
15. Demarest KT, Smith DJ, Azzaro AJ (1980) The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 215: 461-468
16. Elsworth JD, Sandler M, Lees AJ, Ward C, Stern CM (1982) The contribution of amphetamine metabolites of (-)deprenyl to its antiparkinsonian properties. J Neural Transm 54: 105-110
17. Fowler CJ, Tipton KF (1984) On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol 36: 111-115
18. Fowler CJ, Oreland L, Marcusson J, Winblad B (1980) Titration of human brain monoamine oxidase A and B by deprenyl and clorgyline. Naunyn Schmiedebergs Arch Pharmacol 311: 263-272
19. Francis A, Pierce LB, Roth JA (1985) Cellular localization of MAO-A and B in brain. Evidence from kainic acid lesions in striatum. Brain Res 334: 59-64
20. Gervas JJ, Muradas V, Bazan E, Aguado BS, de Yebenens JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278-282
21. Green AR, Mitchell BD, Tordoff AFC, Youdim MBH (1977) Evidence for dopamine deamination of both type A and B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptaminc. Br J Pharmacol 60: 343-349
22. Guldberg HC, Marsden CA (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role, Pharmacol Rev 27: 135-206
23. Heikkila RE, Cabbat E, Manzino L, Duviosin RC (1981) Potentiation by deprenyl of L-Dopa induced circling in nigral lesioned rats. Pharmacol Biochem Behav 15: 75-79
24. Hovevey-Sion D, Kopin U, Stull RW, Goldstein DS (1989) Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology 28: 791-797
25. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285-1297
26. Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and E-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neureichem 60(1): 137-144
27. Karoum F, Chuang EW, Eisler T, Calne DB, Eiebowitz MR, Quitkin FM, Klein DF, Wyatt RJ (1982) Metabolism of (-)deprenyl to amphetamine and metamphetamine may be responsible for deprenyl's therapeutic benefit: a biological assessment. Neurology 32: 503-509
28. Kalo T, Dong B, Ishii K, Kinemuchi H (1986) Brain dialysis: in vivo metabolism of dopamine and serotonine by monoamine oxidase A but not by B in the striatum of unrestrained rats. J Neurochem 46: 1277-1282
29. Kelder D, Fagervall I, Fowler CJ, Ross SB (1989) Regulation of the monoamine concentration in the rat brain by intraneuronal monoamine oxidase. Biogen Amines 6: 1-14
30. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393-408
31. König, JFR, Klippel RA (1963) The rat brain: a stereotaxic atlas of the forebrain and low parts of the brain stem. Williams and Wilkins, Baltimore
32. Levitt P, Pintar JE, Breakefield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79: 6385-6389
33. Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE (1993) Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 341: 1605
34. Linden IB, Nissenen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P (1988) Favourable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental model of Parkinson's disease. J Pharmacol Exp Ther 247(1): 289-293
35. Maj J, Rogoz G, Skuza G, Sowinski H, Superata J (1990) Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm [P-D Sect] 2: 101-112
36. Männistö PT, Toumainen P (1991) Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn Schmiedebergs Arch Pharmacol 344: 412-418
37. Nissinen E, Linden EB, Schultz E, Kaakkola S, Männistö PT, Pohto P (1988) Inhibition of catechol-O-methyltransferase by two novel disubstituted catechol in the rat. Eur J Pharmacol 153: 263-269
38. Parkinson Study Group (1993) A controlled trial of lazahemide (Ro 19-6327) in untreated Parkinson's disease. Ann Neurol 33: 350-356
39. Parkinson Study Group (1994) A controlled trial of lazahemide (Ro 19-6327) in levodopa treated Parkinson's disease. Arch Neurol 51: 342-347
40. Pieri M, Pieri L, Saner A, Da Prada M, Heavely W (1975) A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5,6-dihydroxytryptamine or 6-hydroxytryptamine. Arch Int Pharmacol Ther 217(1): 118-130
41. Pieri M, Schaffner R, Pieri L, Da Prada M, Heavily W (1978) Turning in MFB-lesioned rats and antagonism of neuroleptic induced catalepsy after lisuride and LSD. Life Sci 22: 1615-1622
42. Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267-271
43. Reynolds JP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 543-544
44. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1994) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/ carbidopa action in parkinsonian patients. Neurology 44: 2685-2688
45. Roth JA, Freor K (1978) Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem Pharmacol 27: 1606-1608
46. Sharpless NN, Meunter MD, Tyce GM, Owen CA (1972) 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-DOPA therapy of patients with Parkinson's disease. Clin Chim Acta 37: 359-369
47. Schoepp DD, Azzaro AJ (1981) Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem 36: 2025-2031
48. Stenström A, Hardy J, Oreland L (1987) Intra- and extradopamine-synaptosomal localization of monoamine oxidase in striatal homogenates from four species. Biochem Pharmacol 36: 2931-2935
49. Ungerstedt U, Arbuthnott G (1970) Quantitative recording of rotational behavioral in rats after 6-hydroxy-dopamine lesions of the nigro-striatal dopamine system. Brain Res 24: 485-493
50. Wachtel SR, Abercrombie ED (1994) L-3,4-dihydroxyphenylalanine-induced dopamine release in striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63(1): 108-117
51. Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-Dopa at the blood brain barrier. Life Sci 17: 131-136
52. Waldmeier PC, Delini-Stula A, Maitre L (1976) Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn Schmiedebergs Arch Pharmacol 292: 9-14
53. Yang HYT, Neff NH (1973) β-phenylethylamine: a specific substrate for type B monoamine oxidase in the brain. J Pharmacol Exp Ther 187: 365-371
54. Yang HYT, Neff NH (1974) The monoamine oxidase of the brain: selective inhibition with drugs and the consequences for the metabolism of biogenic amine. J Pharmacol Exp Ther 189: 733-740
55. Zürcher G, Colzi A, Da Prada M (1990) Ro 40-7592: inhibition of COMT in rat brain an extracerebral tissues. J Neural Transm [Suppl] 32: 375-380